Drug class
Second-generation irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor
Mechanism of action
Irreversibly inhibits EGFR/HER1, HER2 and HER4 kinase activity and selected activating EGFR mutations, blocking receptor-mediated downstream signalling and tumour-cell proliferation.
General use cases
- First-line treatment of adults with metastatic non-small-cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutation, as detected by an approved test under the US product indication
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
